Nanomedicine for prion disease treatment

McCarthy, J. Michael; Appelhans, Dietmar; Tatzelt, Jörg; Rogers, Mark

doi:10.4161/pri.24431

Cited by 22 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…80,83,176 One final consideration is directed to the efficiency of the applied one-pot reactions mentioned above to establish the desired dendritic glycoconjugates. 10,[108][109][110][111][112][113][114][115][116][117][118] The conversion of dendritic polyamine scaffold based on amidation, phenyl isothiocyanate derivatives and lactone derivatives is more or less quantitative ( Fig. 6) when following the experimental protocols.…”

Section: Synthetic Aspects Of Dendritic Glycopolymersmentioning

confidence: 99%

“…1,33,35 On the other hand dendritic glycoconjugates, carbohydrate-containing dendronized polymers, and hybrid materials of various polysaccharides over the last year have been also established in various application fields. Thus they have been used as drug delivery systems, 10, biosensors, 15,16,19,[96][97][98][99][100][101] and imaging agents, 1,18,[102][103][104][105][106] but also as a base in biohybrid structures obtained through non-covalent and biological conjugation, 91,92,107,108 as sugarballs for H-bond-active therapeutics and diagnostics for brain disease, [109][110][111][112][113][114][115][116][117][118] as supramolecular structures by (defined) self-assembly [119][120][121] or host-guest interactions, 122 and in thin film technology for introducing specific interactions with small analyte molecules or proteins. 123,124 The PPI, Lys, and PAMAM polyamine dendrimers, but also branched poly(ethyleneimines) (PEI) are the dominating dendritic core scaffolds to realize the desired dendritic glycopolymers for these growing research fields ( Fig.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dendritic glycopolymers based on dendritic polyamine scaffolds: view on their synthetic approaches, characteristics and potential for biomedical applications

et al. 2015

Self Cite

View full text Add to dashboard Cite

In this review we highlight the potential for biomedical applications of dendritic glycopolymers based on polyamine scaffolds. The complex interplay of the molecular characteristics of the dendritic architectures and their specific interactions with various (bio)molecules are elucidated with various examples. A special role of the individual sugar units attached to the dendritic scaffolds and their density is identified, which govern ionic and H-bond interactions, and biological targeting, but to a large extent are also responsible for the significantly reduced toxicity of the dendritic glycopolymers compared to their polyamine scaffolds. Thus, the application of dendritic glycopolymers in drug delivery systems for gene transfection but also as therapeutics in neurodegenerative diseases has great promise.

show abstract

Section: Synthetic Aspects Of Dendritic Glycopolymersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dendritic glycopolymers based on dendritic polyamine scaffolds: view on their synthetic approaches, characteristics and potential for biomedical applications

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…The use of nanoparticles for delivery of anti-inflammatory agents has also been described for Escherichia coli -induced meningitis 87 and demonstrated that a water-soluble malonic acid derivative of carboxyfullerene could reduce CNS levels of TNFα and IL-1β and inhibit neutrophil infiltration across the BBB. In other reports, nanoparticle systems comprised of dendrimers with multiple reactive surface groups have also demonstrated anti-prion activity in part through alteration of the conformation of misfolded prion proteins (reviewed by McCarthy et al 88 ), and maltotriose modified poly (propyleneimine) dendrimers have been shown to be capable of crossing the BBB. 89 …”

Section: Nanomedicines For Infectious Diseasesmentioning

confidence: 99%

Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Gendelman

Anantharam

Bronich

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

106

View full text Add to dashboard Cite

Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics are immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.

show abstract

“…[ 114 ] As per earlier studies polyamine dendrimers remove PrPSc by dragging them to lysosomal degradation. [ 115 ] Ai Tran et al utilized polyelectrolyte multilayer‐coated AuNPs functionalized with primary amines and sulfonates to hinder the accretion of PrPSc in neuroblastoma cells at low doses. [ 116 ] In another report, Sousa et al demonstrated the use of amine functionalized AuNPs for BBB penetration to enter in the distinct neuronal structures where the PrP aggregation takes place.…”

Section: Bbb Modifications and Noninvasive Delivery Of Nanomedicine Imentioning

confidence: 99%

Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics

Mukherjee

Madamsetty

Bhattacharya

et al. 2020

Adv Funct Materials

107

View full text Add to dashboard Cite

Recent times have witnessed an upsurge in the incidence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Prion disease, and amyotrophic lateral sclerosis. The treatment of the same remains a daunting challenge due to the limited access of therapeutic moieties across the blood–brain barrier. Engineered nanoparticles with a size less than 100 nm provide multifunctional abilities for solving these biomedical and pharmacological issues due to their unique physico‐chemical properties along with capability to cross the blood–brain barrier. Needless to mention, there is a scarcity of review articles summarizing recent developments of various nanomaterials including liposomes, polymeric nanoparticles, metal nanoparticles, and bio‐nanoparticles toward the therapeutic and theranostics applications for various neurodegenerative disorders. Here, a broad spectrum of nanomedicinal approaches to eradicate neurodegenerative disorders is provided, along with a brief account of neuroprotection and neuronal tissue regeneration, current clinical status, issues related to safety, toxicity, challenges, and future outlook.

show abstract

Nanomedicine for prion disease treatment

Cited by 22 publications

References 28 publications

Dendritic glycopolymers based on dendritic polyamine scaffolds: view on their synthetic approaches, characteristics and potential for biomedical applications

Dendritic glycopolymers based on dendritic polyamine scaffolds: view on their synthetic approaches, characteristics and potential for biomedical applications

Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics

Contact Info

Product

Resources

About